First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Pheon Therapeutics
Seagen Inc.
Fusion Pharmaceuticals Inc.
Blueprint Medicines Corporation
Incyte Corporation
NiKang Therapeutics, Inc.
Pfizer
Lyell Immunopharma, Inc.
Dana-Farber Cancer Institute
Pfizer
Seagen Inc.
Seagen Inc.
Haihe Biopharma Co., Ltd.
Sunnybrook Health Sciences Centre
Fate Therapeutics
Zai Lab (Hong Kong), Ltd.
Novartis
AbbVie
University of California, San Diego
University of Alabama at Birmingham
Calando Pharmaceuticals